Home » Posts tagged with » Metastatic breast cancer
Olema Oncology raises $54m for breast cancer drug candidate OP-1250

Olema Oncology raises $54m for breast cancer drug candidate OP-1250

Olema Oncology, a California-based biopharma company focused on developing targeted therapies for women’s cancers, has raised $54 million in a Series B financing round, which was co-led by BVF Partners, Logos Capital, and Janus Henderson Investors. The US biopharma company will use the proceeds for advancing OP-1250, its lead drug candidate in breast cancer, into […]

MONARCH 2 clinical trial results : Verzenio, fulvestrant combo improves overall survival in metastatic breast cancer

MONARCH 2 clinical trial results : Eli Lilly and Company (Lilly) said that Verzenio (abemaciclib) in combination with fulvestrant delivered a statistically significant improvement in overall survival in the phase 3 MONARCH 2 clinical trial held for a type of metastatic breast cancer. The US pharma giant said that the MONARCH 2 clinical trial results […]

Continue reading …
Pharma giants bag Lynparza EMA approval for metastatic breast cancer

Lynparza EMA approval : Pharma giants AstraZeneca and MSD have secured an expansion of the European Medical Agency’s (EMA) approval for their poly ADP-ribose polymerase (PARP) inhibitor Lynparza (olaparib) to be used for the treatment of a type of advanced breast cancer. The expanded Lynparza EMA approval allows the PARP inhibitor to be used as […]

Continue reading …
Ibrance FDA approval : Pfizer breast cancer drug approved for metastatic breast cancer in men

New Ibrance FDA approval : The US Food and Drug Administration (FDA) has extended the approval of Pfizer breast cancer drug Ibrance (palbociclib) to cover the treatment of hormone receptor positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in male patients. Latest Ibrance FDA approval Under the new indication approved […]

Continue reading …